Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study...
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
About this item
Full title
Author / Creator
Beck, Lisa A. , Thaçi, Diamant , Deleuran, Mette , Blauvelt, Andrew , Bissonnette, Robert , de Bruin-Weller, Marjolein , Hide, Michihiro , Sher, Lawrence , Hussain, Iftikhar , Chen, Zhen , Khokhar, Faisal A. , Beazley, Bethany , Ruddy, Marcella , Patel, Naimish , Graham, Neil M. H. , Ardeleanu, Marius and Shumel, Brad
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Background
Management of moderate-to-severe atopic dermatitis (AD) commonly requires long-term treatment.
Objective
The aim of this study was to report the safety and efficacy of dupilumab treatment for up to 3 years in adults with moderate-to-severe AD.
Methods
This ongoing, multicenter, open-label extension study (LIBERTY AD OLE; N...
Alternative Titles
Full title
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7371647
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7371647
Other Identifiers
ISSN
1175-0561
E-ISSN
1179-1888
DOI
10.1007/s40257-020-00527-x
